MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types and is often associated with poor prognosis, creating new therapeutic opportunities while also exposing critical challenges in accurately detecting complex biomarkers for precision oncology trials. In Europe, limitations in testing capabilities and regulatory alignment continue to delay clinical trial enrolment and therapeutic progress.
In this webinar, SOPHiA GENETICS, in partnership with ARC Regulatory, will discuss how a comprehensive genomic profiling approach powered by SOPHiA’s AI-driven analytics and supported by ARC Regulatory’s expertise in assay implementation and workflow validation is accelerating Clinical Trial Application development, reducing regulatory risk, and enabling faster, more accurate identification of MTAP-deleted patients to broaden and expedite clinical trial recruitment across Europe.
Key Highlights:
- Understanding MTAP Deletion
Explore the clinical relevance of MTAP deletion as a predictive biomarker for targeted therapies and examine the limitations of current testing approaches. - Innovative Genomic Profiling
Discover the agile, modular comprehensive genomic profiling approach of MSK-IMPACT® powered by SOPHiA DDM™, enabling tailored biomarker coverage with the flexibility to integrate RNA and HRD analysis as needed. - Accelerating European Trial Recruitment
Learn how SOPHiA GENETICS and ARC Regulatory are enabling rapid and accurate identification of MTAP-deleted patients to support faster clinical trial enrolment across Europe. - Reducing Regulatory Risk
Understand how integrated assay implementation and workflow validation streamline Clinical Trial Application development and mitigate regulatory complexity.
Why Attend?
- Stay ahead of evolving biomarker strategies in precision oncology
- Gain actionable insights into overcoming European regulatory and testing challenges
- Learn practical approaches to shortening clinical trial recruitment timelines
- Understand how AI-powered genomic technologies are transforming patient identification
- Engage directly with industry leaders during the live Q&A session
If you are involved in oncology clinical development, biomarker strategy, regulatory affairs, or clinical trial operations, this webinar will provide valuable, real-world insights into accelerating precision oncology research in Europe.
Webinar Leaders
James Lappin
Associate Director Global Regulatory – ARC Regulatory
Lina Li
Product Marketing Director – Application, SOPHiA GENETICS
Sofia Lima
BioPharma Marketing Manager, SOPHiA GENETICS
You May Also Be Interested In…
Learn More About Autoimmune
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
